Which pill works best for bipolar depression? huge study aims to find out
NCT ID NCT06433635
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This large study compares four FDA-approved medications for bipolar depression to see which one helps people feel better. Over 2,700 adults with bipolar I or II disorder and current depression will be randomly assigned to one of the drugs. The goal is to find which treatment leads to remission, meaning fewer depressive symptoms and improved well-being.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cariprazine, Quetiapine, Lurasidone, Aripiprazole/Escitalopram
What this could lead to
If successful, this trial could identify which medication is most effective for treating bipolar depression, helping doctors choose better treatments.
What could go wrong
This is a pragmatic trial comparing existing drugs, so no new breakthrough is expected. Results may not apply to all patients, and side effects like nausea or sedation are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEPRESSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Case Western Reserve University
Cleveland, Ohio, 44106-1712, United States
-
John Hopkins
Baltimore, Maryland, 21218, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
McLean Hospital
Belmont, Massachusetts, 02478, United States
-
Montefiore Medical Center and Albert Einstein College of Medicine
New York, New York, 10461, United States
-
Nagy Youssef
Grand Rapids, Michigan, 49548, United States
-
New York University Grossman School of Medicine NYU
New York, New York, 10016, United States
-
Steve Strakowski
Bloomington, Indiana, 47405, United States
-
UT Health Houston Texas
Houston, Texas, 77030, United States
-
UT Southwestern Medical Center
Dallas, Texas, 75390-7208, United States
-
University of Alabama Birmingham
Birmingham, Alabama, 35294, United States
-
University of British Columbia
Vancouver, British Columbia, V6T 1Z4, Canada
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of New Mexico Health Sciences Center Albuquerque
Albuquerque, New Mexico, 87131-0001, United States
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Pittsburgh
Pittsburgh, Pennsylvania, 15260, United States
-
University of Texas at Austin
Austin, Texas, 78712, United States